Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The company is headquartered in Cambridge, Massachusetts and currently employs 24 full-time employees. The company went IPO on 2020-01-30. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The firm is advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. Its BDTX-4933 pipeline product is out-licensed to Servier. BDTX-4933 is designed to target RAS and RAF alterations in solid tumors. The company is exploring partnership opportunities for its FGFR2/3 selective development candidate BDTX-4876.
Follow-Up Questions
Qui est le CEO de Black Diamond Therapeutics Inc ?
Dr. Mark Velleca est le Chairman of the Board de Black Diamond Therapeutics Inc, il a rejoint l'entreprise depuis 2021.
Quelle est la performance du prix de l'action BDTX ?
Le prix actuel de BDTX est de $3.97, il a decreased de 0.99% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de Black Diamond Therapeutics Inc ?
Black Diamond Therapeutics Inc appartient à l'industrie Biotechnology et le secteur est Health Care
Quelle est la capitalisation boursière de Black Diamond Therapeutics Inc ?
La capitalisation boursière actuelle de Black Diamond Therapeutics Inc est de $226.0M
Est-ce que Black Diamond Therapeutics Inc est un achat, une vente ou un maintien ?
Selon les analystes de Wall Street, 7 analystes ont établi des notations d'analystes pour Black Diamond Therapeutics Inc, y compris 4 achat fort, 6 achat, 1 maintien, 0 vente et 4 vente forte
